Epigenomics AG Receives Allowance for Key Technology Patent in Japan

Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products

15-Mar-2010 - Epigenomics AG announced that it received a Notice of Allowance by the Japanese Patent Office stating that they intend to grant a patent for Epigenomics' HeavyMethyl(TM) technology. This notification is equivalent to a "Rule 71(3) notification" by the European Patent Office. Patent application ...

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

04-Nov-2009 - Epigenomics AG announced that Quest Diagnostics Incorporated successfully completed the clinical validation of its Septin9-based laboratory-developed test for aiding the detection of colorectal cancer. Under terms of a license agreement between the companies for Epigenomics' proprietary DNA ...

Epigenomics AG: Clinical Study Shows Lead Biomarker for Lung Cancer also works in Blood

Biomarker mSHOX2 could accelerate diagnostic work-up of patients with suspected lung cancer

27-Aug-2009 - Epigenomics AG announced that it successfully completed a clinical feasibility study in lung cancer. This study has confirmed Epigenomics' proprietary lead biomarker mSHOX2 for lung cancer diagnosis when tested in blood samples. In this study the amount of methylated DNA of the SHOX2 gene ...

Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories

ARUP to commercialize laboratory-developed blood test based on Epigenomics' mSEPT9 biomarker to aid in the early detection of colorectal cancer

14-Aug-2009 - Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to develop a ...

Novel German Research Alliance to Detect Precursors of Colorectal Cancer

Munich Technical University, Epigenomics AG and KVB to develop novel approaches to cancer prevention

28-May-2009 - The German Federal Ministry of Education and Research will fund a clinical research project for the early detection of colorectal cancer, to be realized by an alliance of Scientists from the 2nd Medical Clinic of the University vHospital rechts der Isar at the Munich Technical University, the ...

Epigenomics AG Receives Allowances for Key Patents in Europe

Patents cover biomarker mPITX2 for prostate and breast cancer indications

20-May-2009 - Epigenomics AG announced that it has received Rule 71(3) notifications stating that the European Patent Office intends to grant two patent for Epigenomics' PITX2 DNA methylation biomarker (mPITX2). This notification is equivalent to a "Notice of Allowance" by the United States Patent and ...

Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics

27-Feb-2009 - Epigenomics AG announced that it has entered into a non-exclusive licensing agreement for its proprietary biomarker mGSTP1 with U.S.-based Quest Diagnostics Incorporated. Under the agreement, Quest Diagnostics has obtained rights to uses of the GSTP1 DNA methylation biomarker (mGSTP1) to ...

Sysmex and Epigenomics AG Announce Strategic R&D Collaboration in Colorectal Cancer Diagnostics

Parties entered into negotiations for a non-exclusive IVD license to mSEPT9 colorectal cancer blood test

26-Jan-2009 - Sysmex Corporation and Epigenomics AG announced that they have signed a strategic research and development collaboration agreement in molecular diagnostics. Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex' molecular diagnostics instrumentation for ...

Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation

15-Jan-2008 - Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary Scorpions® technology for R&D use and research kits, as well as an option to expand ...

Epigenomics AG Forms Medical Advisory Board for Colorectal Cancer Screening

High-profile board to support Epigenomics in development and commercialization of its colorectal cancer screening test in the U.S.

11-Oct-2007 - Epigenomics AG announced the formation of its Colorectal Cancer Medical Advisory board and the appointment of its first four members. The board will advise Epigenomics on important aspects of the clinical development and commercialization process of the colorectal cancer screening test in the US. ...